Most Read Articles
Tristan Manalac, 17 Nov 2020
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
Jairia Dela Cruz, 18 Nov 2020
The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).

Bariatric surgery helps resolve NASH, fibrosis over time

01 Nov 2020

Bariatric surgery promotes the long-term resolution of nonalcoholic steatohepatitis (NASH) and the progressive regression of fibrosis over time, a new study has found.

The researchers conducted a prospective analysis of 180 severely obese patients (mean age, 46.7 years) who had biopsy-proven NASH. Patients underwent bariatric surgery and were followed for 5 years. Liver biopsies were available for 125 participants at 1 year, and for 64 at 5 years.

The primary endpoint was NASH resolution without the worsening of fibrosis, which occurred in 84.4 percent of patients 5 years after bariatric surgery. This resolution came with improvements in all the histological components of NASH. The median NAS likewise dropped from 5 to 1 in the same time interval (p<0.001).

In addition, 87.5 percent of the participants saw improvement in hepatocellular ballooning, and 59.4 percent had the same experience with regard to lobular inflammation. Baseline NASH severity was unrelated to its resolution 5 years later.

Bariatric surgery also had strong impacts on body mass index (BMI). In majority of the patients (61.3 percent), BMI dropped by <10 percent 5 years after the surgery; only 11.3 percent saw a BMI reduction of ≤5 percent.

In line with the principal study findings, fibrosis likewise improved significantly at 5 years, with the median score dropping from 1.5 at baseline to 0 at follow-up (p<0.001). Majority (70.2 percent) of the patients saw such an improvement. The change in fibrosis was progressive, according to the researchers, with reductions becoming apparent a year after surgery, which continued until 5 years.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 17 Nov 2020
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
Jairia Dela Cruz, 18 Nov 2020
The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).